Allogeneic transplantation remains the most definitive curative option for patients with acute myeloid leukemia (AML). However, given the median age of diagnosis of AML in the late 60s, patients and clinicians have been reluctant to offer transplant to many in the older population. In this age group, AML presents with higher risk molecular and cytogenetic phenotype and patients' comorbidities, performance status, frailty and life views all impact the decision-making about whether to proceed with transplantation. Recent analyses suggest promising outcomes and thus acknowledgement of chronological age should be tempered with assessments of performance status, frailty, donor availability and careful balancing of a patient's wishes, life goals and understanding of the risks before restricting access of older patients to the curative potential of allotransplantation.
Bibliographical noteFunding Information:
The author receives research support from Incyte and from FATE Therapeutics, both unrelated to this work. Supported in part by funding from the NIH to the CIBMTR through: U24CA076518 , U24HL138660 and U24CA233032 .
© 2021 Elsevier Ltd
- Allogeneic transplant
- Non-relapse mortality
PubMed: MeSH publication types
- Journal Article
- Research Support, N.I.H., Extramural